Cargando…

DDEL-16. UNDERSTANDING OPTIMAL CONVECTION-ENHANCED DELIVERY PHYSICO-CHEMICAL INFUSION PARAMETERS: THE ROLE OF BBB EFFLUX PUMPS IN DRUG DISTRIBUTION AND CLEARANCE

BACKGROUND: Diffuse midline gliomas harboring the H3K27M mutation are aggressive and universally fatal brain tumors that primarily occur in children. The blood-brain barrier (BBB) prevents many drugs from reaching the tumor at cytotoxic concentrations and efflux pumps found on the epithelial cells o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Power, Erica, Zhang, Liang, Daniels, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Drug Delivery/Pharmacokinetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715363/ http://dx.doi.org/10.1093/neuonc/noaa222.051

Ejemplares similares

DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Sasaki, Takahiro, et al.
Publicado: (2020)

DDEL-08. CONVECTION-ENHANCED DELIVERY OF NIMUSTINE HYDROCHLORIDE (ACNU) AGAINST PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Saito, Ryuta, et al.
Publicado: (2020)

DDEL-07. A PHASE I STUDY EXAMINING THE FEASIBILITY OF INTERMITTENT CONVECTION-ENHANCED DELIVERY (CED) OF MTX110 FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED DIFFUSE MIDLINE GLIOMAS
por: Zacharoulis, Stergios, et al.
Publicado: (2020)

DDEL-07. A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas (DMGs)
por: Zacharoulis, Stergios, et al.
Publicado: (2022)

DDEL-17. TRIPLE INTRAVENTRICULAR CHEMOTHERAPY FOR TREATMENT OF RELAPSED CHOROID PLEXUS CARCINOMA
por: Lau, Grace, et al.
Publicado: (2020)

DDEL-12. NANOPARTICLE DELIVERY OF DOXORUBICIN FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Ung, Caitlin, et al.
Publicado: (2020)

DDEL-04. ENGINEERED NANOCARRIERS TO ENHANCE DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER
por: Straehla, Joelle P, et al.
Publicado: (2020)

DDEL-02. Intra-arterial Delivery for Novel Combinatorial Chemotherapies in Choroid Plexus Carcinoma
por: Martin, Brice, et al.
Publicado: (2022)

DDEL-01. ENHANCING DRUG DELIVERY WITH MRgFUS FOR DIFFUSE INTRINSIC PONTINE GLIOMA MODEL
por: Ishida, Joji, et al.
Publicado: (2020)

DDEL-15. NANOTHERAPEUTIC TARGETING OF TUMOR ENDOTHELIUM FOR ENHANCING DRUG DELIVERY PAST THE BLOOD-BRAIN BARRIER
por: Kiguchi, Hiro, et al.
Publicado: (2020)

DDEL-14. SAFETY OF INTERVENTRICULAR METHOTREXATE ADMINISTRATION FOLLOWING RADIATION IN PEDIATRIC PATIENTS WITH MALIGNANT BRAIN TUMORS
por: Rosales, Kristofer, et al.
Publicado: (2020)

DDEL-03. The use of programmable valves as a vehicle for intrathecal chemotherapy delivery in infants with CNS tumors and hydrocephalus.
por: Dvir, Rina, et al.
Publicado: (2022)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

DDEL-05. Intraventricular therapy with topotecan is feasible and safe: Experience in 50 pediatric patients with various malignant brain tumors
por: Peyrl, Andreas, et al.
Publicado: (2022)

DDEL-06. Drug Delivery to the Pons Using Short-Pulse Focused Ultrasound and Microbubble Exposure for the Treatment of Diffuse Midline Glioma
por: Chattenton, Dani, et al.
Publicado: (2022)

DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS
por: Stepien, Natalia, et al.
Publicado: (2020)

DDEL-06. DRUG INTERACTION BETWEEN EVEROLIMUS AND CANNABIDIOL IN PEDIATRIC PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: A SINGLE INSTITUTION EXPERIENCE
por: Sabus, Ashley, et al.
Publicado: (2020)

DDEL-09. HIGH DOSE MTX110 (SOLUBLE PANOBINOSTAT) SAFELY ADMINISTERED INTO THE FOURTH VENTRICLE IN A NON-HUMAN PRIMATE MODEL
por: Sirianni, Rachael W, et al.
Publicado: (2020)

DDEL-05. BLOOD-BRAIN BARRIER DISRUPTION AND ENHANCED RADIOSENSITIZERS EXTRAVASATION UPON FOCUSED ULTRASOUND FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Hart, Elvin ‘t, et al.
Publicado: (2020)

DDEL-13. FOCUSED ULTRASOUND MEDIATED BLOOD BRAIN BARRIER DISRUPTION IN A MURINE MODEL OF PONTINE GLIOMA: A SAFETY AND FEASIBILITY STUDY
por: Englander, Zachary, et al.
Publicado: (2020)

DDEL-04. Pharmacokinetic/Pharmacodynamic analysis of the DNA methyltransferase inhibitor 5-azacytidine shows adequate brain tissue penetration with intravenous administration in a DIPG mouse patient-derived xenograft model.
por: Groves, Andrew, et al.
Publicado: (2022)

DDEL-02. DECREASED TOXICITY OF CONVENTIONAL DOSE CHEMOTHERAPY UTILIZING BODY WEIGHT INSTEAD OF BODY SURFACE AREA FOR DOSING IN YOUNG CHILDREN <6 YEARS OLD ENROLLED ON THE “HEAD START” 4 CLINICAL TRIAL
por: Dhall, Girish, et al.
Publicado: (2020)

Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?
por: Germovsek, Eva, et al.
Publicado: (2016)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS‐986231 in Healthy Volunteers
por: Cowart, Douglas, et al.
Publicado: (2019)

ROS Modulating Inorganic Nanoparticles: A Novel Cancer Therapeutic Tool
por: Newton Amaldoss, Maria John, et al.
Publicado: (2022)

Recent Patents on Nasal Vaccines Containing Nanoadjuvants
por: Candela, Francesco, et al.
Publicado: (2022)

Optimizing and Evaluating the Transdermal Permeation of Hydrocortisone Transfersomes Formulation Based on Digital Analysis of the In Vitro Drug Release and Ex Vivo Studies
por: Abdelwahd, Asmae, et al.
Publicado: (2022)

HGG-13. BRAIN DISTRIBUTION AND CLEARANCE OF ALISERTIB IS LIMITED BY PGP AND BCRP EFFLUX PUMPS AND DEPENDENT UPON DELIVERY METHOD
por: Power, Erica, et al.
Publicado: (2021)

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers*
por: Zecca, Ernesto, et al.
Publicado: (2015)

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting
por: Shannon, Richard J, et al.
Publicado: (2014)

Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
por: Størset, Elisabet, et al.
Publicado: (2014)

Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians
por: Hasunuma, Tomoko, et al.
Publicado: (2016)

Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non‐obese volunteers
por: Chairat, Kalayanee, et al.
Publicado: (2016)

Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
por: Jonsson, E. Niclas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6ufunn06tmf7p5g0rf50me2ojt